News Search Results
Oct 23, 2025, 06:01 ET NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), an advanced clinical-stage
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 22, 2025, 10:58 ET University of Bridgeport's Master of Science in Human Nutrition Program Earns Eight-Year Accreditation
personalized nutrition care. Accreditation also ensures that the program fulfills all eligibility requirements for the Certified Nutrition Specialist (CNS) credential, an industry benchmark for advanced nutrition professionals, offered by the Board of Certification of Nutrition Specialists (BCNS).
More news about: University of Bridgeport
Oct 22, 2025, 08:30 ET Offline Studio Partners with Corundum Neuroscience and Corundum Systems Biology for New Life Sciences Venture Creation
Oct. 22, 2025 /PRNewswire/ -- Corundum Neuroscience (CNS), the neuroscience venture builder and fund, and Corundum Systems Biology (CSB),
More news about: Corundum Neuroscience
Oct 22, 2025, 07:00 ET Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, C.A. No. 21-00691; Jazz Pharmaceuticals, Inc. et al v. Avadel CNS Pharmaceuticals, LLC, C.A. No. 21-01138; Jazz Pharmaceuticals, Inc. et al v. Avadel CNS Pharmaceuticals, LLC, C.A. No. 21-01594; Avadel CNS Pharmaceuticals, LLC et
More news about: Alkermes plc; Avadel Pharmaceuticals plc
Oct 21, 2025, 18:08 ET Cohen & Steers Infrastructure Fund, Inc. Declares Distributions for November and December 2025
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Oct 21, 2025, 12:00 ET HOPCo showcases digital patient engagement and strategic partnerships at 2025 AAHKS Annual Meeting
HOPCo CNS (Clinical Network Solutions), its comprehensive platform for optimizing musculoskeletal care delivery across multiple practices and care settings.
More news about: Healthcare Outcomes Performance Company
Oct 21, 2025, 08:43 ET Alethios Launches to Lower the Barriers to Human Health Research
Main Stage Innovation Showcase at CNS Summit, the premier life sciences conference — demonstrating its reach across both pharma and non-pharma research.
More news about: Alethios, Inc.
Oct 21, 2025, 08:00 ET Breakthrough clinical trial confirms that GammaTile delivers superior tumor control compared to standard of care for patients with newly diagnosed operable brain metastases
randomized controlled trial for treatment of newly diagnosed metastatic brain tumors (ROADS, NCT04365374). Presented at: Congress of Neurological Surgeons (CNS) Annual Meeting; October 15, 2025; Los Angeles, CA. Lamba N, Wen PT, Aizer AA. Epidemiology of brain metastases and leptomeningeal
More news about: GT Medical Technologies
Oct 20, 2025, 21:20 ET SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform
Biopharmaceuticals, Co., Ltd., a biotech company focusing on research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and oncology worldwide, today announced the establishment of Mentis Care, Inc., a joint venture with a leading Brazil-based pharmaceutical company,
More news about: SK Biopharmaceuticals. Co., Ltd.
Oct 20, 2025, 05:00 ET FDA Grants Orphan Drug Designation to Cellenkos' CK0803 Tregs for Treatment of Amyotrophic Lateral Sclerosis
Orphan Drug Designation granted to CK0803 for Amyotrophic Lateral Sclerosis CK0803 is CNS Homing Tregs expressing CXCR3hi, CXCR7+, LFA1+ CK0803 is planned for Randomized Placebo
More news about: Cellenkos, Inc.
Oct 20, 2025, 01:56 ET Chengdu CATANIA's Tower 2 Debuts Globally: A 222-Meter-High Sky Residence Redefining Global Luxury Living.
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- A news report from CNS: Recently, a wave of discerning homebuyers from different cities has been converging on Chengdu CATANIA. International elites
More news about: CNS
Oct 18, 2025, 06:00 ET Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Oct 17, 2025, 08:30 ET Cohen & Steers Infrastructure Fund, Inc. Announces Preliminary Results of Transferable Rights Offering
https://www.cohenandsteers.com/Symbols: (NYSE: CNS, UTF)
More news about: Cohen & Steers, Inc.
Oct 16, 2025, 20:00 ET XLC Memilih Corero Network Security Untuk Tingkatkan Pertahanan DDoS di Seluruh Lokasi Baru di Asia Pasifik
Corero Network Security (AIM: CNS) (OTCQX: DDOSF) adalah perusahaan terdepan yang diakui di bidang perlindungan DDoS dan yang terbaik dalam hal ketersediaan layanan adaptif di waktu nyata.
More news about: Corero Network Security
Oct 16, 2025, 16:27 ET COHEN & STEERS REPORTS RESULTS FOR THIRD QUARTER 2025
NEW YORK, Oct. 16, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended September 30, 2025. The earnings release along with the accompanying earnings presentation can be viewed
More news about: Cohen & Steers, Inc.
Oct 16, 2025, 13:59 ET Vivistim Co-Founder Named Innovator of the Year by the Congress of Neurological Surgeons
"We're proud of Navzer for being named CNS' Innovator of the Year," said Richard Foust, CEO of MicroTransponder. "His pioneering work on Paired VNS Therapy continues to help stroke survivors reclaim meaningful lives. The growing real-world evidence presented at the CNS Annual Meeting and the enthusiastic
More news about: MicroTransponder Inc.
Oct 16, 2025, 09:00 ET Connecticut Innovations' AI/Q Fund Invests in Two Frontier AI Opportunities: Yuma Asset Management and Bexorg
neurodegenerative diseases such as Alzheimer's and Parkinson's, with potential to expand into a broad range of CNS diseases. Over time, Bexorg aims to accelerate strategic partnerships and internal CNS development programs with its integrated AI and precision neurology platform. "These
More news about: Connecticut Innovations
Oct 16, 2025, 08:45 ET Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis
3:12.MS is characterized by focal lymphocytic CNS infiltration leading to myelin destruction and axonal damage, which result in neurologic syndromes and physical disability3. MS clinical manifestations depend on the location of lesions in the CNS. Symptoms may include sensory and visual disturbances;
More news about: IASO Bio
Oct 16, 2025, 08:30 ET Deconstructing OCD Through the Use of Multiple Operant Behavioral Tasks in Rodents, Upcoming Webinar Hosted by Xtalks
TORONTO, Oct. 16, 2025 /PRNewswire/ -- Despite decades of research, the development of central nervous system (CNS) drugs continues to face significant challenges. The majority of compounds targeting psychiatric indications fail in clinical trials, including an unmet
More news about: Xtalks
Oct 16, 2025, 08:05 ET Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Oct 15, 2025, 16:30 ET Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
neurological conditions. Viatris received rights to develop and commercialize pitolisant and Spydia®, two assets in the Central Nervous System (CNS) therapy area, further expanding Viatris' portfolio of innovative products in Japan. As part of the transaction, Viatris has acquired
More news about: Viatris Inc.
Oct 15, 2025, 11:54 ET Electronic Grade SiH₄ Silane Gas Market to Reach $5.36B by 2031, Driven by Semiconductors & Solar | Valuates Reports
derivatives for solar and semiconductor use. Taiyo Nippon Sanso, Mitsui Chemicals, SIAD, Inner Mongolia Xingyang Technology, CNS, and ACE Gases. The top five companies control approximately 47% of the global market. Their strategies
More news about: Valuates Reports
Oct 15, 2025, 10:00 ET Metastatic Brain Tumor Collaborative Announces First-Ever Collaborative Grant Opportunity Focused on CNS Metastasis
innovative projects aimed at improving the diagnosis, treatment, and understanding of central nervous system (CNS) metastases. This represents the first-ever collaborative grant opportunity dedicated to CNS metastasis, made possible through the collective effort of ten leading nonprofit cancer organizations.
More news about: American Brain Tumor Association
Oct 15, 2025, 08:00 ET Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood
More news about: Indivior PLC
Oct 15, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
Conference Panel "Battleground States for Muscular Dystrophies": Tuesday, October 21 at 2:00 p.m. ET Panel "CNS GT – Lessons from Mature Programs & the Field's Next Frontiers": Tuesday, October 21 at 2:45 p.m. ET Location: New York, NY
More news about: REGENXBIO Inc.